626,958 Shares in Icon Plc $ICLR Purchased by Sound Shore Management Inc. CT

Sound Shore Management Inc. CT acquired a new stake in Icon Plc (NASDAQ:ICLR) during the first quarter, according to its most recent 13F filing with the SEC. The fund acquired 626,958 shares of the medical research company’s stock, valued at approximately $69,379,000. Sound Shore Management Inc. CT owned 0.78% of Icon as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Toth Financial Advisory Corp bought a new stake in Icon during the 4th quarter valued at $27,000. EFG International AG bought a new position in Icon in the 4th quarter worth about $27,000. Abound Financial LLC bought a new position in Icon in the 4th quarter worth about $54,000. Johnson Financial Group Inc. purchased a new position in Icon during the 3rd quarter valued at about $71,000. Finally, Blue Trust Inc. grew its holdings in Icon by 207.5% during the 1st quarter. Blue Trust Inc. now owns 658 shares of the medical research company’s stock valued at $73,000 after buying an additional 444 shares in the last quarter. 95.61% of the stock is owned by hedge funds and other institutional investors.

Icon Price Performance

Shares of Icon stock opened at $170.00 on Monday. The firm has a market capitalization of $13.02 billion, a PE ratio of 30.25, a price-to-earnings-growth ratio of 8.34 and a beta of 1.22. The business’s 50-day moving average price is $146.22 and its 200-day moving average price is $136.69. The company has a current ratio of 1.14, a quick ratio of 1.14 and a debt-to-equity ratio of 0.31. Icon Plc has a 12 month low of $66.57 and a 12 month high of $211.00.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on ICLR shares. Royal Bank Of Canada upgraded shares of Icon from a “sector perform” rating to an “outperform” rating and raised their price objective for the company from $126.00 to $185.00 in a research report on Thursday, June 25th. Jefferies Financial Group reaffirmed a “buy” rating and set a $165.00 target price on shares of Icon in a report on Friday, May 29th. Bank of America raised their price target on shares of Icon from $125.00 to $150.00 and gave the company an “underperform” rating in a report on Thursday, June 25th. TD Cowen boosted their price target on shares of Icon from $164.00 to $197.00 and gave the company a “buy” rating in a research report on Thursday, June 25th. Finally, Citigroup upped their price target on shares of Icon from $140.00 to $165.00 and gave the stock a “neutral” rating in a report on Thursday, June 25th. Nine analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $173.19.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.